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The lung carcinoma has an increasing trend in the Czech Republic. These findings 
correspond to the fact that lung carcinoma is the most common type of cancer worldwide.  
Carbonyl reducing enzymes occur in different types of tissues, and they are 
responsible for the development of inflammation, cancer, and cancer resistance. These 
NADPH-dependent oxidoreductase cause the reduction of carbonyl groups to alcohol 
compound and decrease the toxicity of drug for tumor cells. Last but not least, these 
enzymes are responsible for tumor cell proliferation, differentiation, and increased 
tumoral aggressivity.  
This work aimed to study the inhibition effect of chosen cyclin-dependent kinase 
inhibitors (CDKi) on the activity of Aldo-keto reductases. Besides inhibition of CDK, the 
ability to inhibit efflux transporters and carbonyl reducing enzymes was proved at CDK 
inhibitors.  
The inhibition effect of tepotinib, entrectinib and sapanisertib was determined by 
UHPLC analysis. The most significant inhibition potential to AKR1C3 was observed at 
tepotinib 50 µM (70,57 % of enzyme was inhibited). Thus tepotinib was selected for 
further tests. The value of IC50 of tepotinib was calculated in the range 8,48 – 12,20 µM, 
and the value of inhibitory constant was in the range 4,38 +/- 0,65 µM. The experiment 
shows that tepotinib is a competitive inhibitor.  
We can assume that the combination of cytostatic and inhibitors of CDK may 
increase the effect of the treatment and eliminate the occurrence of side effects of 
conventional treatment.  
 
